PeptiDream Inc (4587):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PeptiDream Inc (4587) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8231
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform that helps to produce peptide libraries for the identification of highly potent and selective hit candidates. Its technologies include flexizyme; translation, cyclization, and peptide modifying technologies; and PD display. PeptiDream’s technologies enables the production of peptide libraries for the development of peptide-based products. PeptiDreamoffers products for the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis, and others. The company collaborates with other biotechnology and drug development companies to receive contracts and research and development support funds, and target proteins. It also has its presence in Tokyo, Japan. PeptiDream is headquartered in Kawasaki, Japan.

PeptiDream Inc (4587) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PeptiDream Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PeptiDream Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
PeptiDream to Acquire Drug Discovery Research Business from PharmaDesign 12
Venture Financing 13
Modulus Discovery Raises USD7.2 Million in Series A Financing 13
Private Equity 14
Taiyo Pacific Partners Acquires Minority Stake in PeptiDream 14
Partnerships 15
PeptiDream Enters into Co-Development Agreement with Santen Pharma 15
Bayer and PeptiDream Enter into Partnership 16
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 17
Heptares Therapeutics and PeptiDream Enter into Agreement 18
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 19
PeptiDream Enters into Agreement with Janssen Pharma 20
PeptiDream Enters into Research Agreement with BIND Therapeutics 21
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 22
PeptiDream Enters into Agreement with Genentech 23
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 24
Teijin Pharma Enters into Discovery Agreement with PeptiDream 25
PeptiDream Enters into Discovery Agreement with Sanofi 26
PeptiDream Enters into Peptide Discovery Agreement with Merck 27
PeptiDream Expands Drug Discovery Agreement with Novartis 28
PeptiDream Enters into Agreement with Tokyo Metropolitan Institute of Medical Science 29
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 30
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 31
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 32
PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 33
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 34
Licensing Agreements 35
Eli Lilly Enters into Licensing Agreement with PeptiDream 35
Shionogi Enters into Licensing Agreement with PeptiDream 36
PeptiDream Enters Into Licensing Agreement With Eli Lilly 37
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 38
PeptiDream Exercises Option for Licensing Agreement with Novartis 39
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 40
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 41
Equity Offering 42
PeptiDream Raises USD53 Million in IPO 42
PeptiDream Inc – Key Competitors 43
PeptiDream Inc – Key Employees 44
PeptiDream Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Corporate Communications 46
Aug 22, 2017: PeptiDream Appoints Representative Directors 46
Government and Public Interest 47
Nov 09, 2017: PeptiDream Receives Grant to Discover and Develop Novel Therapeutics for Infectious Disease 47
Product News 48
Sep 25, 2017: PeptiDream and Kawasaki Medical School Announce Novel Muscle Atrophy Inhibitor for the Treatment of Duchenne Muscular Dystrophy 48
Other Significant Developments 49
Nov 13, 2017: PeptiDream Announces 2 nd Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck & Co., Inc., Kenilworth, N.J., U.S.A 49
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck 50
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin 51
May 31, 2017: PeptiDream Announces 5 th Milestone from Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb 52
Mar 22, 2017: PeptiDream Announces 1st Milestone from Macrocyclic Peptide Drug Discovery Alliance with Shionogi 53
Feb 14, 2017: PeptiDream Announces the Selection of Development Candidate from Discovery Collaboration with Daiichi Sankyo 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
PeptiDream Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PeptiDream Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PeptiDream Inc, Deals By Therapy Area, 2012 to YTD 2018 9
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PeptiDream to Acquire Drug Discovery Research Business from PharmaDesign 12
Modulus Discovery Raises USD7.2 Million in Series A Financing 13
Taiyo Pacific Partners Acquires Minority Stake in PeptiDream 14
PeptiDream Enters into Co-Development Agreement with Santen Pharma 15
Bayer and PeptiDream Enter into Partnership 16
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 17
Heptares Therapeutics and PeptiDream Enter into Agreement 18
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 19
PeptiDream Enters into Agreement with Janssen Pharma 20
PeptiDream Enters into Research Agreement with BIND Therapeutics 21
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 22
PeptiDream Enters into Agreement with Genentech 23
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 24
Teijin Pharma Enters into Discovery Agreement with PeptiDream 25
PeptiDream Enters into Discovery Agreement with Sanofi 26
PeptiDream Enters into Peptide Discovery Agreement with Merck 27
PeptiDream Expands Drug Discovery Agreement with Novartis 28
PeptiDream Enters into Agreement with Tokyo Metropolitan Institute of Medical Science 29
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 30
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 31
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 32
PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 33
PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 34
Eli Lilly Enters into Licensing Agreement with PeptiDream 35
Shionogi Enters into Licensing Agreement with PeptiDream 36
PeptiDream Enters Into Licensing Agreement With Eli Lilly 37
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 38
PeptiDream Exercises Option for Licensing Agreement with Novartis 39
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 40
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 41
PeptiDream Raises USD53 Million in IPO 42
PeptiDream Inc, Key Competitors 43
PeptiDream Inc, Key Employees 44
PeptiDream Inc, Other Locations 45

List of Figures
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PeptiDream Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[PeptiDream Inc (4587):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Support.com, Inc. (SPRT):企業の財務・戦略的SWOT分析
    Support.com, Inc. (SPRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Asseco Poland SA (ACP):企業の財務・戦略的SWOT分析
    Summary Asseco Poland SA (Asseco) is a technology company that offers information processing solutions. The company provides products such as proprietary software and services, third party software and services; and hardware and infrastructure. Asseco also offers services that include cloud services …
  • Joslin Diabetes Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Joslin Diabetes Center (Joslin) is a healthcare service provider that offers diabetes treatment, research and education services. The center provides services such as weight management programs, pregnancy program, eye care, diabetes prevention, research, diabetes patient education, adult dia …
  • Electricity Supply Board:電力:M&Aディール及び事業提携情報
    Summary Electricity Supply Board (ESB) owned by Irish Government, is a diversified and vertically integrated utility that generates, transmits, and distributes and supplies electricity and gas. The company builds, owns and maintains transmission and distribution networks. It offers meter reading, an …
  • Deutsche Biotech Innovativ AG (VUA):製薬・医療:M&Aディール及び事業提携情報
    Summary Deutsche Biotech Innovativ AG (DBI), formerly Venetus Beteiligungen AG, is a biotechnology company that develops drug candidates on indications sepsis and cancer. The company’s products comprise Adrecizumab, DB1RA and AB2302. It diagnostic based drug development approach and offers identific …
  • SolarWorld Industries GmbH:企業の戦略的SWOT分析
    SolarWorld Industries GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that …
  • Federal Signal Corporation:企業の戦略・SWOT・財務分析
    Federal Signal Corporation - Strategy, SWOT and Corporate Finance Report Summary Federal Signal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Olam International Ltd:戦略・SWOT・企業財務分析
    Olam International Ltd - Strategy, SWOT and Corporate Finance Report Summary Olam International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Mitek Systems Inc (MITK):企業の財務・戦略的SWOT分析
    Summary Mitek Systems Inc (Mitek) is a technology company that develops and markets payment and fraud prevention software products. The company offers products such as Mobile Verify, Mobile Docs, Mobile Fill, Mobile Deposit and Multi Check Capture. Its Mobile Verify is a Mitek's ID verification solu …
  • Tabuk Pharmaceuticals Manufacturing Company:製薬・医療:M&Aディール及び事業提携情報
    Summary Tabuk Pharmaceuticals Manufacturing Company (Tabuk), a subsidiary of Astra Industrial Group, is a drug company that develops, manufactures and markets branded generic pharmaceuticals and under-licensed products. The company offers products in various therapeutic areas including alimentary tr …
  • Karolinska Development AB (KDEV):企業の財務・戦略的SWOT分析
    Summary Karolinska Development AB (Karolinska Development) is a life sciences investment company that develops innovations from science into commercial products. The company invests in start up's and growth of the pharmaceutical, medical device and biotechnology companies that develop specialty care …
  • Versantis AG-製薬・医療分野:企業M&A・提携分析
    Summary Versantis AG (Versantis), is a preclinical stage pharmaceutical company which offers new medicines and diagnostics for treating liver diseases. It’s lead pipeline product VS-01, capable of removing toxic agents from the organism and save patients from prescription and illicit drug overdoses. …
  • Vinnolit GmbH & Co KG:企業の戦略的SWOT分析
    Vinnolit GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Symrise AG (SY1):製薬・医療:M&Aディール及び事業提携情報
    Summary Symrise AG (Symrise) offers flavors and fragrances. The company develops, produces and sells flavorings, fragrances, cosmetic active ingredients and raw materials, and functional ingredients and solutions for the cosmetics industry. It also provides biofunctional and bioactive ingredients an …
  • UGI Corporation (UGI)-石油・ガス分野:企業M&A・提携分析
    Summary UGI Corporation (UGI) is a holding company providing energy products and services. Through a network of subsidiaries, the company stores, transports, distributes and markets energy products and related services. It serves as a domestic and international retail distributor of propane and buta …
  • Adacel Technologies Limited:企業の戦略・SWOT・財務情報
    Adacel Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary Adacel Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Co-operative Group Ltd:企業の戦略・SWOT・財務分析
    Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Fischer Connectors UK:企業の戦略・SWOT・財務情報
    Fischer Connectors UK - Strategy, SWOT and Corporate Finance Report Summary Fischer Connectors UK - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ProAxsis Ltd:製品パイプライン分析
    Summary ProAxsis Ltd (ProAxsis), formerly ProAx-Sis Ltd, a subsidiary of NetScientific UK Ltd, is a developer of novel, point of care tests for the monitoring of patients with chronic diseases. The company develops proteasetags based point of care tests to offer a visual readout of active proteases …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆